Brief: Astellas Pharma Inc - Astellas Confirms Phase 2 Gleam Trial Did Not Meet Primary Endpoint Of Overall Survival In Patients With Metastatic Pancreatic Cance
14/10/2025 24:31
Oct 14 (Reuters) - Astellas Pharma Inc 4503.T: ASTELLAS PHARMA INC: ASTELLAS CONFIRMS PHASE 2 GLEAM TRIAL DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH METASTATIC PANCREATIC CANCE ASTELLAS PHARMA INC: IMPACT OF THIS RESULT ON ASTELLAS' FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2026, IS EXPECTED TO BE MINOR Source text: ID:nTSvm8bbb7 Further company coverage: 4503.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)